Citigroup Downgrades Acumen Pharmaceuticals to Neutral, Lowers Price Target to $1

Benzinga · 3d ago
Citigroup analyst Geoff Meacham downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) from Buy to Neutral and lowers the price target from $5 to $1.